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or hospital), and the MICs as determined by the broth microdilution method. In this preliminary analysis of 39 sites across 
the US, the non-susceptibility of S. pneumoniue to penicillin closely matched that of recent national surveillance studies with 
intermediate non-susceptibility of 31% and high-level penicillin resistance of 14%. Among the antibiotics tested, the 
quinolones were the most active; against S. pneumoniae, moxifloxacin was more active than trovafloxacin, which was more 
active than levofloxacin. These data outline an effective approach to generating comparative regional and national 
susceptibility data against the common respiratory tract pathogens. 
20. Chlamydia pneumoniae infection in community aquired pneumonia (CAP) 
patients in Tartu 
H. LILL, H. LEESIK AND E. LAJA 
Tartu University Lung Hospital, Estonia 
Aims: The aim of the study was to verify the role of Chlamydia pneumoniae in the aethiology of CAP 
Material and method: we prospectively analyzed case histories, medical records and investigations of Chlamydia pneumoniae 
antibodies in 70 hospitalized CAP patients (mean age 48 yrs.) in the Tartu University Lung Hospital in 1999. Clamydia 
pneumoniae antibodies were measured by ELISA method and the results were presented in enzyme immune units (EIU). The 
signs of acute infection (IgA>8, and/or positive IgMr1.1, IgGs30 EIU) were found in 44 patients (63%), (mean age 52 yrs.) 
The mean value for IgA was 41.9 EIU (ranging from 10 to 179), and for IgG 132.3 EIU (ranging from 31 to 383.8). 26 
patients (mean age 40 yrs.) did not satisfy the criteria of Chlumydia pneumoniae infection. There were no Chlamydia 
pneumoniue antibodies in 19 (27%) of patients, IgG antibody was identified in 7 (10%) of patients. 
A second concurrent respiratory pathogen (Mycoplasma pneumoniae, B. pertussis or other typical bacteria) was found in 17 
(39%) acute Chlamydiapneumoniae cases. All patients predominately suffered from acute clinical symptoms. 
In conclusion: Chlamydia pneumoniae is an important aethiological agent in hospitalized CAP patients in our hospital, mainly 
in patients 50 years and over. 
21. Community acquired pneumonia (CAP&diagnostic relevance of bronchoalveolar 
lavage (BAL) 
M. KUREPKAT, M. RAFFENBERG”, H. MAUCH+ AND H.LoDE* 
*Department of Chest and Infectious Diseases and tlnstitute for Medical Microbiology, Chest Hospital 
Heckeshorn, Berlin, Germany 
Quantitative BAL is an accepted diagnostic tool in nosocomial and ventilator associated pneumonia-the position of this 
bronchoscopic technique in CAP however is unclear. Between 1992 and 1996 149 patients (68.5% males) with finally 
diagnosed CAP underwent BAL. BAL passed for positive if the following criterias were fulfilled: 104 cfu/ml or qualitative 
proof of P carinii. A positive bacteriological diagnosis by BAL was possible in 48.3% of these patients. Leading pathogens 
were Gram-positive cocci (14.8%) and l? carinii (14.8%) followed by H. inzuenca (9.4%). A previous antibiotic therapy did not 
reduce positive BAL results (47.3% vs. 50.0%). Complications of bronchoscopy were temporary. Results of BAL induced a 
change of antibiotic treatment in 85.0% of patients with positive BAL findings. Quantitative BAL contributes significantly to 
a precise diagnosis and treatment of CAP 
22. Fluoroquinolone kill against Streptococcus pneumoniae 
J. GEORGE AND I. MORRISSEY 
GR Micro Ltd, London, UK. 
The bactericidal activity of the fluoroquinolones (FLQs) levofloxacin (LEV), ciprofloxacin (CIP), ofloxacin (OFL), 
moxifloxacin (MOX) or grepafloxacin (GRE) between 0.003 and 200 mg/l was assessed in Mueller Hinton broth (& 5% (v/v) 
lysed horse blood) over 3 h at 37 “C. Three penicillin-susceptible clinical isolates of S. pneumoniae (SP) were used; SP 007 
(OFL MIC 1 mg/l); SP 303 (OFL MIC 4 mg/l) and SP 181 (OFL MIC 32 mg/l). After incubation, viable counts were made on 
blood agar and log change in viability was plotted against log drug concentration. Kill was compared relative to individual 
drug pharmacokinetics by calculating bactericidal indices (BIs) from these plots (J Antimicrob Chemother 1997, 39: 713). BIs 
were calculated as the AUC of each kill curve at bactericidal concentrations up to serum Cmax (Smax) or lung tissue Cmax 
(Lmax) using data from published literature after single 400 or 500 mg oral doses. 
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Smax BI/Lmax BI 
Smax BI/Lmax BI 
Smax BI/Lmax BI 
1.80.9 1.00.5 0.411.5 08/18 0.310.5 
0.110.2 0.310.6 o.o/o.o 0.010.3 O~O/O.O 
0~010~0 o.o/o.o O.O/O~O O~O/O~O O~O/O~O 
Each FLQ was bactericidal against SP 007, with LEV being the most bactericidal FLQ using either Smax or Lmax BI 
breakpoints. All the FLQs tested showed less kill against SP 303, as would be expected. Only LEV or MOX showed an Smax 
BI against this strain. However, with Lmax breakpoints, GRE was slightly more bactericidal than LEV and MOX was the 
most bactericidal. To conclude, of the FLQs tested, LEV or MOX should retain bactericidal activity against infections caused 
by FLQ-intermediate SP. However, none of the FLQs were bactericidal against the OFL-resistant SP 18 1 and therefore would 
not be expected to show bactericidal activity against infections caused by FLQ-resistant SI? 
23. Does appropriate antibiotic treatment influence outcome in 
community-acquired pneumonia (CAP)? 
M. NIEDERMAN, D. CHURCH, J. KAUFMANN AND M. SPRINGSKLEE 
Background: Community-acquired pneumonia (CAP) is a common cause of morbidity throughout the world with an 
estimated incidence of 12 cases per 1000 people per year. Mortality has been estimated by the WHO to be between 500 000 
and 1.4 million deaths per year. As such, it is a major cost to the health services of all countries and treatment should be as 
appropriate as possible. 
Objective: To compare the hospitalization and mortality rates in 4 multi-national trials in patients with CAP treated with 
either moxifloxacin (MXF) or comparitor (amoxicillin [AMOX] or clarithromycin [CLAR]). 
Methods: Pooled patient data were subjected to meta-analysis. The number of deaths in all our controlled CAP studies was 
determined by defining deaths as those that occurred within 30 days of the end of treatment. 
Results: Among 701 MXF-treated patients there were 4 deaths (0.57%) compared to 12 deaths among the 705 comparitor- 
treated patients (1.70%; P=O.O45). Thirty-nine of the 701 (5.6%) MXF-treated patients were hospitalized compared to 43 
(6.1%) comparitor-treated patients. 
Conclusions: Across four controlled clinical trials of CAP, the mortality rate for moxifloxacin-treated patients was significantly 
better than that for comparitor-treated patients. In addition, slightly more patients treated with the comparitor agents were 
hospitalized compared to those treated with moxifloxacin. 
24. More common microbiological agents responsible of acute exacerbation of 
COPD in a northern area of Italy 
M. PECIS, M. SCOZZAFAVA, A. CERAMINIELLO* AND F. MARCHESANI 
Department of Pneumology, *Microbiology Laboratory, Ospedale Maggiore, Lodi, Italy. 
There is not an universally accepted definition of acute exacerbation of COPD. A descriptive definition could be: “an acute, 
episodic deterioration superimposed on stable COPD with: increased dyspnoea, reduced daily performance, with or without 
changes in sputum volume and colour, coughing, or body temperature; and/or alteration in mental status” (Eur Respir Man, 
1998, 7,264). Many are the causes of acute exacerbation of COPD (AECB); in over half cases the ethiology is an infection of 
the tracheobronchial tree. 
The aim of the study is the detection of the more common microbiological agents responsible of AECB along a period of 
one year. 
From October 1998 to September 1999, 567 patients (80.3% males, 19.7% females) affected by respiratory diseases were 
admitted in our Department. AECB was diagnosed in 71 cases (12.5%, mean age 7222 yrs, 52 males and 19 females). In only 
7 patients the microbiological samples (smear or broncoscopy aspirated) were positive. The agents detected were: 5 Pseudo- 
monas Aer., 2 Streptococcus Pn., 2 Haemophilus InJuenzae, 2 St. Aureus, 1 Acrobacter Xyloxidans, 1 Serratia Marcescens, 1 
Enterobacter Aerogenes. 
Our hospital is active in a country area in southern Padana Plain (PO river area) with continental climate, mean temperature 
of 26/30” C in summer and g/10-12” C in winter; relative humidity is 70/80% in summer and 54/74% in winter. The most 
prevalence of AECB was observed in February-May period. This fact may be due to the climate variations. 
Pseudomonas Aer. is not usually described as the more common cause of infective AECB. Our data may be related to the 
age of the patients (elderly). 
